In chronic myeloid leukemia (CML), BCR-ABL-mediated oncogenic signaling can be
successfully targeted with the BCRABL-inhibitors imatinib, nilotinib, and dasatinib leading to …

The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the
outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory …

The discovery of new drugs has occasionally led to a better understanding of biologic
processes and unforeseen therapeutic applications. One such example is the new group of …

In chronic myeloid leukemia (CML), the translocation t (9; 22) results in the fusion protein
BCR-ABL (breakpoint cluster region-abelson murine leukemia), a tyrosine kinase mediating …

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder caused by excessive
granulopoiesis due to the formation of the constitutively active tyrosine kinase BCR-ABL. An …

Chronic myelogenous leukemia (CML) is caused by the BCR-ABL chimeric tyrosine kinase,
which is derived from the reciprocal translocation, t (9; 22)(q34; q11). BCR-ABL tyrosine …

Bcr-Abl tyrosine kinase has been validated as a molecular target for the treatment of chronic
myelogenous leukemia (CML). More recently, it has been reported that CML patients could …

The twenty-first century is beginning with a sharp turn in the field of cancer therapy.
Molecular targeted therapies against specific oncogenic events are now possible. The BCR …

BCR-ABL1 plays a key role in the pathogenesis of chronic myeloid leukemia (CML), and it
has been investigated as a druggable target of tyrosine kinase inhibitors (TKIs) over two …

Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR–ABL, has shown
remarkable clinical activity in patients with chronic myelogenous leukaemia (CML) …